Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 2/20 | 0.44 |
| ▸ | ACHE | P22303 | 2/20 | 0.44 |
| ▸ | HTR4 | Q13639 | 14/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 3/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.38 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.38 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.38 |
| ▸ | HTR2C | P28335 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL598741 | 0.94 | BCHE (0.46) | BCHEACHEHTR4CYP1A2CYP2C9 | |
| Hydrochloric Acid SCHEMBL599500 | 0.94 | BCHE (0.45) | BCHEACHEHTR4CYP1A2CYP2C9 | |
| SCHEMBL598726 | 0.93 | CHRM1 (0.45) | BCHEACHEHTR4CYP1A2CYP2C9 | |
| SCHEMBL599770 | 0.91 | BCHE (0.44) | BCHEACHEHTR4ALDH1A1RAB9A | |
| SCHEMBL597820 | 0.91 | BCHE (0.46) | BCHEACHEHTR4CYP1A2CYP2C9 | |
| SCHEMBL599124 | 0.90 | HTR4 (0.44) | BCHEACHEHTR4CYP1A2CYP2C9 | |
| SCHEMBL598276 | 0.89 | CNR1 (0.43) | BCHEACHEHTR4CYP1A2CYP2C9 | |
| Hydrochloric Acid SCHEMBL597406 | 0.88 | HTR4 (0.43) | BCHEACHEHTR4CYP1A2CYP2C9 | |
| SCHEMBL598412 | 0.87 | BCHE (0.44) | BCHEACHEHTR4ALDH1A1RAB9A | |
| SCHEMBL597888 | 0.87 | HTR4 (0.48) | HTR4KCNH2HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2445877-B1 | BICYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | NANOTHERAPEUTICS INC (US) | 2014-07-23 | — | — | EP | claimed |
| EP-2445877-A2 | BICYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | Nanotherapeutics, Inc. (US) | 2012-05-02 | — | — | EP | claimed |
| US-8114894-B2 | Bicyclic compounds and methods of making and using same | NANOTHERAPEUTICS, INC. (US) | 2012-02-14 | — | — | US | claimed |
| US-20100197723-A1 | BICYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | NANOSHIFT, LLC | 2010-08-05 | — | — | US | claimed |
| WO-2010065743-A2 | BICYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | NANOTHERAPEUTICS, INC. (US) | 2010-06-10 | — | — | WO | claimed |
| EP-2445877-B1 | BICYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | NANOTHERAPEUTICS INC (US) | 2014-07-23 | — | — | EP | disclosed |
| EP-2445877-A2 | BICYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | Nanotherapeutics, Inc. (US) | 2012-05-02 | — | — | EP | disclosed |
| US-20120088793-A1 | Bicyclic Compounds and Methods of Making and Using Same | NANOTHERAPEUTICS, INC. | 2012-04-12 | — | — | US | disclosed |
| US-8114894-B2 | Bicyclic compounds and methods of making and using same | NANOTHERAPEUTICS, INC. (US) | 2012-02-14 | — | — | US | disclosed |
| US-20100197723-A1 | BICYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | NANOSHIFT, LLC | 2010-08-05 | — | — | US | disclosed |
| WO-2010065743-A2 | BICYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | NANOTHERAPEUTICS, INC. (US) | 2010-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120088793-A1 | Bicyclic Compounds and Methods of Making and Using Same | HTR2C, HTR3A, HTR3C | BCHE 367/4885ACHE 300/4885HTR4 7/4885 |
| US-20100197723-A1 | BICYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | HTR2C, HTR3A, HTR3C | BCHE 367/4885ACHE 300/4885HTR4 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.